

2008

## Program at a glance

WEDNESDAY 7™ MAY	THURSDAY 8™ MAY	FRIDAY 9™ MAY	SATURDAY 10™ MAY	SUNDAY MAY 11 <sup>TH</sup>
	O9:00 - 10:30 a.m.  ACADEMIC SESSION 1  Definitions, epidemiology and global risks of the metabolic syndrome Chair: Paoletti R. (Italy) Hermans M. (Belgium) Farinaro E. (Italy) Smith S. (USA)	09:00 - 10:30 a.m.  ACADEMIC SESSION 2 Emerging therapies Chair: Kastelein J. (The Netherlands) Arnal J.F. (France) Carmena R. (Spain) Brewer B. (USA)	09:00 - 10:30 a.m.  ACADEMIC SESSION 3  Prevention of Diabetes and Cardiovascular Disease  Chair: Calvo C. (Chile)  Mancini F. P. (Italy)  Assmann G. (Germany)  Davidson M. (USA)	09:00 - 11:00 a.m.  Poster session & Reward  Chair: Fruchart JC. (France)
	10:30 - 11:00 a.m.  COFFEE BREAK	10:30 - 11:00 a.m. COFFEE BREAK	10:30 - 11:00 a.m. COFFEE BREAK	
	SYMPOSIUM SPONSORED BY SOLVAY PHARMACEUTICALS Type 2 Diabetes. Focus on microvascular complications Chair: Fruchart JC. (France) Crepaldi G. (Italy) Keech A. (Australia) Brown V. (USA) Dodson P. (UK)	SYMPOSIUM SPONSORED BY ASTRAZENECA The Unaware coronary patient : 2 clinical cases Chairs: Fruchart JC. (France) - Bruckert E. (France) Krempf M. (France) Kownator S. (France) Bruckert E. (France)	11:00- 11:45 a.m.  STATE OF THE ART LECTURE Chair: Smith S. (USA) Koenig W. (Germany)  11:45 a.m 12:30 p.m.  STATE OF THE ART LECTURE Chair: Brewer B. (USA) Robins S. (USA)	
	12:30 - 02:00 p.m.  LUNCH DEBATE SPONSORED BY ASTRAZENECA Antiplatelet therapy: how to proceed with surgery or invasive diagnostic procedures?  Thiefin G. (France)  Albaladejo P. (France)  Montalescot G. (France)	12:30 - 02:00 p.m.  LUNCH DEBATE SPONSORED BY SANOFI-AVENTIS  Cardiometabolic risk in diabetes  Charpentier G. (France)  James P. (UK)	12:30 - 02:00 p.m.  LUNCH	END OF THE CONGRESS
	O2:00 - 03:30 p.m.  FONDATION CŒUR ET ARTÊRES SYMPOSIUM 1  Treatment of dyslipidemia in the metabolic syndrome Chairs: Betteridge J. (UK) - Davignon J. (Canada)  Taskinen MR. (Finland)  Schaefer EJ. (USA)  Fruchart JC. (France)	O2:00 - 04:00 p.m.  FONDATION CŒUR ET ARTÈRES SYMPOSIUM 2  Is there an impact of the pleiotropic effects of lipid lowering drugs in the treatment of the metabolic syndrome?  Chairs: Taskinen MR. (Finland) - Schaefer E. J. (USA) Betteridge J. (UK) Davignon J. (Canada) Marx N. (Germany) Duriez P. (France)	O2:00 - 03:30 p.m.  ACADEMIC SESSION 4  Metabolic abnormalities and psychological complications associated with the Metabolic Syndrome and Diabetes  Chair: Crepaldi G. (Italy)  Olsson A.G. (Sweden)  Ceska R. (Czech Republic)  Maggi S. (Italy)	
	03:30 - 04:00 p.m.  Coffee Break	04:00 - 04:30 p.m.  COFFEE BREAK	03:30 - 04:00 p.m.  COFFEE BREAK	
06:00 - 07:00 p.m. CONGRESS OPENING CEREMONY Fruchart JC. (France)	Symposium sponsored by KOWA  Management of HDL-C - Experience with a new statin  Chair: Fruchart JC. (France)  Steinmetz A. (Germany)  Sasaki J. (Japan)  Kastelein J. (The Netherlands)  Fruchart JC. (France)	Symposium sponsored by TAKEDA The type 2 diabetic patient, the updated situation or what is really new? Chair: Charpentier G. (France) Avignon A. (France) Charpentier G. (France) Staels B. (France) Lincoff M. A.	04:00 - 05:00 p.m.  ORAL COMMUNICATION SELECTED FROM ABSTRACTS Chair: Duriez R. (France) Benlian P. (France) Escher G. (Suisse) Joannes M.O (Guyane) Hubacek J.A. (Czech Republic)	